SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register

-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Capital measures Heidelberg (euro adhoc) - SYGNIS´ reduction of share capital in a 3:1 ratio was entered in the commercial register Heidelberg, 15 December 2010 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today announced the registration of the capital reduction in the commercial register on the basis of the resolution of the Annual General Meeting held on 30 November 2010. Hereby the share capital is reduced from EUR 41,258,643 to EUR 13,752,881, allocated to 13,752,881 shares outstanding. At the same time the implementation of the capital reduction on the stock exchange and the consolidation of the shares in a 3:1 ratio were initiated. It is expected that the consolidation of the shares will be completed by the end of December 2010. Due to this process the trading of the SYGNIS shares on the stock exchange will be temporarily suspended. The purpose of this capital reduction is primarily to improve the Company´s abilities to interact on the capital markets and to open up financing alternatives, since the Company´s share price has been below the nominal value of EUR 1 for a long period. It is anticipated that this move will better support the development of the shares. About SYGNIS Pharma SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical company listed on the Prime Standard of the German stock exchange. The Company is focused on the research and development of innovative therapies for the treatment of disorders of the Central Nervous System. SYGNIS´ core projects are currently Acute Stroke for which SYGNIS´ lead clinical programme is AX200 as well as the preclinical KIBRA-project for the treatment of different forms of dementia. All these disorders are characterized by the fact that, as the disease progresses, nerve cells are damaged and die. Although there is great medical demand, there are currently no or only inadequate treatment options available. SYGNIS´ strategy for growth includes the development of new products from its own research and through in-licensing and acquisitions. For further information please contact: SYGNIS Pharma AG: Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812 Media-Contact: Julia Phillips Financial Dynamics Tel.: +44 (0) 20 7269 7187 ### Disclaimer Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward- looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### end of announcement euro adhoc -------------------------------------------------------------------------------- Further inquiry note: Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812 Branche: Biotechnology ISIN: DE0005043509 WKN: 504350 Index: CDAX, Prime All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Hamburg / free trade Stuttgart / free trade Düsseldorf / free trade Hannover / free trade München / free trade

Das könnte Sie auch interessieren: